While smaller trials like KEYNOTE-905 can show dramatic results, they are subject to more statistical noise. Larger, thousand-patient studies like B15 and Niagara, with narrower confidence intervals, are considered closer to the true effect size and provide a more stable foundation for establishing the standard of care.

Experts caution that the new consensus definition of cCR, combining imaging and cystoscopy, is for clinical trials only. Applying it prematurely in routine practice could harm patients, as its correlation with true pathologic response is still being validated with modern therapies.

While new FDA-approved intravesical treatments like nadofaragene firadenovec and TAR-200 demonstrate high complete response rates initially, their effectiveness consistently diminishes over time. This highlights the ongoing challenge of achieving durable, long-term bladder preservation.

The trial's 57.1% pathologic complete response (pCR) rate is deceptively conservative. It categorized patients who responded well but declined surgery as non-responders, suggesting the treatment's true biological efficacy is even higher than the already impressive reported figure.

The FDA's critique of both CREST and Potomac trials highlights that while event-free survival (EFS) endpoints were met, the lack of improvement in overall survival or prevention of muscle-invasive disease makes the risk/benefit profile questionable for an early-stage cancer, where treatment-related harm is a primary concern.

In the SUNRISE 2 trial, 44% of patients had no detectable tumor after pre-treatment resection. This high baseline inflates the final clinical complete response (CR) rates (e.g., 59% in the control arm), making CR a misleading indicator of the actual therapeutic benefit, which was a much smaller improvement over baseline.

Due to high unmet medical need in non-muscle invasive bladder cancer, the FDA created a special regulatory pathway. This guidance allows for full marketing approval based on a single-arm, open-label study of just 100 patients, dramatically accelerating the timeline and reducing the cost to bring new therapies to market.

The formal FDA classification of "BCG-unresponsive" bladder cancer created a standardized patient population, which spurred a rapid increase in clinical trials for new therapies. This regulatory clarity was a key inflection point for innovation in the field.

An expert oncologist identified a pathological complete response (pCR) rate over 50% as the benchmark that would fundamentally alter treatment. The EV Pembro trial's 57% pCR rate crossed this threshold, forcing a shift from a surgery-centric model toward bladder preservation strategies and systemic therapy.